Lonza AG Acquires PharmaCell BV

Catalent Acquires MaSTherCell Global from Great Point Partners and Co-investors

February 3, 2020

Biotechnology

Catalent Pharma Solutions has signed a definitive agreement to acquire MaSTherCell Global, a cell and gene therapy CDMO that Great Point Partners had invested in alongside Orgenesis and SFPI-FPIM. MaSTherCell, headquartered in Gosselies, Belgium with a U.S. facility in Houston, Texas, expands Catalent's cell and gene therapy development and manufacturing capabilities and adds significant European and U.S. capacity.

Lonza Group AG Acquires Synaffix B.V.

June 1, 2023

Biotechnology

Lonza Group AG has acquired Synaffix B.V., a Netherlands-based biotech company that commercialises a clinical-stage antibody-drug conjugate (ADC) technology platform. The deal brings Synaffix's ADC bioconjugation technology into Lonza's integrated ADC development and manufacturing offering to accelerate discovery, development, scale-up and commercialization of ADCs.

CellCarta Acquires Biogazelle

December 14, 2021

Biotechnology

CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.

Miltenyi Biotec Acquires lino Biotech

March 22, 2023

Biotechnology

Miltenyi Biotec has acquired 100% of lino Biotech from investors including Roche Venture Fund and Hightech-Grunderfonds. The acquisition brings lino's focal molography biosensor platform into Miltenyi's cell and gene therapy and research-tools portfolio to enhance potency assays and quality-control capabilities.

Title21 Health Solutions Acquires MyCellHub

January 8, 2026

Cloud & SaaS

Title21 Health Solutions, an ArchiMed portfolio company, has acquired Belgium-based MyCellHub to integrate a cloud-based Manufacturing Execution System (MES) into its life-sciences quality management and orchestration platform. The add-on expands Title21's end-to-end offering for cell and gene therapy manufacturing, strengthens compliance and real-time production monitoring capabilities, and extends the company's geographic reach into Europe. Financial terms were not disclosed.

Axol Bioscience Acquires Phenocell

October 21, 2024

Biotechnology

Axol Bioscience Ltd. has fully acquired Phenocell SAS, adding Phenocell’s iPSC-derived skin and retinal cell lines and custom bioassay services to Axol’s drug discovery product portfolio. The acquisition expands Axol’s capabilities into ophthalmology and dermatology (including AMD and cosmetics testing); financial terms were not disclosed.